AGENERASE
LOE ApproachingNDAORALSOLUTION
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral small-molecule antiviral approved in 1999 by GSK. The specific indication and mechanism of action are not documented in available data. The drug is formulated as an oral solution for systemic administration.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting team and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AGENERASE represents a late-stage product career opportunity with declining growth prospects. Roles focus on managing market contraction, preparing for generic competition, and supporting compliance and supply chain stability.
Brand Manager (Generics)Field Sales
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.